Cryoport (CYRX) Misses Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Cryoport Reports First Quarter 2022 Results
May 5, 2022 4:05 PM EDTRevenue of $52.3 million Provides Full Year 2022 Revenue Guidance of $260-$265 millionExpansion and advancement of robust clinical pipeline continues now supporting a record 609 clinical trials, with Phase 3 clinical trials increasing from 69 to 81 year over yearCash and short-term investments of $600 million
NASHVILLE, Tenn., May 5, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three months ended March 31, 2022.
... More